NewLink Genetics Corporation (NASDAQ: NLNK) is one of 188 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare NewLink Genetics Corporation to related companies based on the strength of its risk, profitability, valuation, dividends, analyst recommendations, earnings and institutional ownership.
Insider and Institutional Ownership
45.3% of NewLink Genetics Corporation shares are owned by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 13.7% of NewLink Genetics Corporation shares are owned by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares NewLink Genetics Corporation and its rivals revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|NewLink Genetics Corporation||$35.77 million||-$85.15 million||-3.58|
|NewLink Genetics Corporation Competitors||$213.24 million||-$39.02 million||-66.85|
NewLink Genetics Corporation’s rivals have higher revenue and earnings than NewLink Genetics Corporation. NewLink Genetics Corporation is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
NewLink Genetics Corporation has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, NewLink Genetics Corporation’s rivals have a beta of 1.51, suggesting that their average stock price is 51% more volatile than the S&P 500.
This is a breakdown of recent ratings and price targets for NewLink Genetics Corporation and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|NewLink Genetics Corporation||0||0||6||0||3.00|
|NewLink Genetics Corporation Competitors||500||2378||6539||122||2.66|
NewLink Genetics Corporation presently has a consensus price target of $25.67, indicating a potential upside of 194.01%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.49%. Given NewLink Genetics Corporation’s stronger consensus rating and higher probable upside, equities research analysts clearly believe NewLink Genetics Corporation is more favorable than its rivals.
This table compares NewLink Genetics Corporation and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|NewLink Genetics Corporation||-229.19%||-63.39%||-47.83%|
|NewLink Genetics Corporation Competitors||-3,405.94%||-96.17%||-39.58%|
NewLink Genetics Corporation rivals beat NewLink Genetics Corporation on 7 of the 12 factors compared.
NewLink Genetics Corporation Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.